Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE
Diane L Kamen, Caroline Wallace, Zihai Li, Megan Wyatt, Crystal Paulos, Chungwen Wei, Hongjun Wang, Bethany J Wolf, Paul J Nietert, Gary Gilkeson, Diane L Kamen, Caroline Wallace, Zihai Li, Megan Wyatt, Crystal Paulos, Chungwen Wei, Hongjun Wang, Bethany J Wolf, Paul J Nietert, Gary Gilkeson
Abstract
Background: Reports of clinical improvement following mesenchymal stromal cell (MSC) infusions in refractory lupus patients at a single centre in China led us to perform an explorative phase I trial of umbilical cord derived MSCs in patients refractory to 6 months of immunosuppressive therapy.
Methods: Six women with a SLEDAI >6, having failed standard of care therapy, received one intravenous infusion of 1×106 MSCs/kg of body weight. They maintained their current immunosuppressives, but their physician was allowed to adjust corticosteroids initially for symptom management. The clinical endpoint was an SRI of 4 with no new British Isles Lupus Activity Guide (BILAG) As and no increase in Physician Global Assessment score of >0.3 with tapering of prednisone to 10 mg or less by 20 weeks.
Results: Of six patients, five (83.3%; 95% CI 35.9% to 99.6%) achieved the clinical endpoint of an SRI of 4. Adverse events were minimal. Mechanistic studies revealed significant reductions in CD27IgD double negative B cells, switched memory B cells and activated naïve B cells, with increased transitional B cells in the five patients who met the endpoint. There was a trend towards decreased autoantibody levels in specific patients. Two patients had increases in their Helios+Treg cells, but no other significant T cell changes were noted. GARP-TGFβ complexes were significantly increased following the MSC infusions. The B cell changes and the GARP-TGFβ increases significantly correlated with changes in SLEDAI scores.
Conclusion: This phase 1 trial suggests that umbilical cord (UC) MSC infusions are very safe and may have efficacy in lupus. The B cell and GARP-TGFβ changes provide novel insight into mechanisms by which MSCs may impact disease.
Trial registration number: NCT03171194.
Keywords: Autoimmunity; B-Lymphocytes; Lupus Erythematosus, Systemic.
Conflict of interest statement
Competing interests: None declared.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Kaul A, Gordon C, Crow MK, et al. . Systemic lupus erythematosus. Nat Rev Dis Primers 2016;2:16039. 10.1038/nrdp.2016.39
- Ginzler EM, Dooley MA, Aranow C, et al. . Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219–28. 10.1056/NEJMoa043731
- Sedhain A, Hada R, Agrawal RK, et al. . Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in nepalese population: a randomized control trial. BMC Nephrol 2018;19:175. 10.1186/s12882-018-0973-7
- Maidhof W, Hilas O. Lupus: an overview of the disease and management options. P T 2012;37:240–9.
- Miura M, Gronthos S, Zhao M, et al. . Shed: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A 2003;100:5807–12. 10.1073/pnas.0937635100
- Dominici M, Le Blanc K, Mueller I, et al. . Minimal criteria for defining multipotent mesenchymal stromal cells. the international society for cellular therapy position statement. Cytotherapy 2006;8:315–7. 10.1080/14653240600855905
- Gronthos S, Mankani M, Brahim J, et al. . Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A 2000;97:13625–30. 10.1073/pnas.240309797
- Lee DE, Ayoub N, Agrawal DK. Mesenchymal stem cells and cutaneous wound healing: novel methods to increase cell delivery and therapeutic efficacy. Stem Cell Res Ther 2016;7:37. 10.1186/s13287-016-0303-6
- Grada A, Falanga V. Novel stem cell therapies for applications to wound healing and tissue repair. Surg Technol Int 2016;29:29–37.
- Tse WT, Pendleton JD, Beyer WM, et al. . Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003;75:389–97. 10.1097/01.TP.0000045055.63901.A9
- Di Nicola M, Carlo-Stella C, Magni M, et al. . Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838–43. 10.1182/blood.V99.10.3838
- Forbes GM, Sturm MJ, Leong RW, et al. . A Phase 2 study of allogeneic mesenchymal stromal cells for Luminal crohn’s disease refractory to biologic therapy. Clinical Gastroenterology and Hepatology 2014;12:64–71. 10.1016/j.cgh.2013.06.021
- Christopeit M, Schendel M, Föll J, et al. . Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008;22:1062–4. 10.1038/sj.leu.2404996
- Wang L, Wang L, Cong X, et al. . Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev 2013;22:3192–202. 10.1089/scd.2013.0023
- Wang D, Zhang H, Liang J, et al. . Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 2013;22:2267–77. 10.3727/096368911X582769c
- Liang J, Zhang H, Hua B, et al. . Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010;69:1423–9. 10.1136/ard.2009.123463
- Augello A, Tasso R, Negrini SM, et al. . Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007;56:1175–86. 10.1002/art.22511
- Bonig H, Kuçi Z, Kuçi S, et al. . Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”—outcome report of 92 patients. Cells 2019;8:1577. 10.3390/cells8121577
- Molendijk I, Bonsing BA, Roelofs H, et al. . Allogeneic bone marrow–derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with crohn’s disease. Gastroenterology 2015;149:918–27. 10.1053/j.gastro.2015.06.014
- Wang D, Zhang H, Liang J, et al. . A long-term follow-up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem Cell Reports 2018;10:933–41. 10.1016/j.stemcr.2018.01.029
- Sun L, Wang D, Liang J, et al. . Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis & Rheumatism 2010;62:2467–75. 10.1002/art.27548
- Sun L, Akiyama K, Zhang H, et al. . Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009;27:1421–32. 10.1002/stem.68
- Gu F, Wang D, Zhang H, et al. . Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol 2014;33:1611–9. 10.1007/s10067-014-2754-4
- Deng D, Zhang P, Guo Y, et al. . A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis 2017;76:1436–9. 10.1136/annrheumdis-2017-211073
- Musiał-Wysocka A, Kot M, Majka M. The pros and cons of mesenchymal stem cell-based therapies. Cell Transplant 2019;28:801–12. 10.1177/0963689719837897
- Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014;32:252–60. 10.1038/nbt.2816
- Abdi R, Fiorina P, Adra CN, et al. . Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008;57:1759–67. 10.2337/db08-0180
- Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int 2018;2018:1–12. 10.1155/2018/3057624
- Collins E, Gu F, Qi M, et al. . Differential efficacy of human mesenchymal stem cells based on source of origin. J Immunol 2014;193:4381–90. 10.4049/jimmunol.1401636
- Gao L, Bird AK, Meednu N, et al. . Bone marrow-derived mesenchymal stem cells from patients with systemic lupus erythematosus have a senescence-associated secretory phenotype mediated by a mitochondrial antiviral signaling protein-Interferon-β feedback loop. Arthritis & Rheumatology 2017;69:1623–35. 10.1002/art.40142
- Carrion F, Nova E, Ruiz C, et al. . Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010;19:317–22. 10.1177/0961203309348983
- Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism 1997;40:1725. 10.1002/art.1780400928
- Jolly M, Kosinski M, Garris CP, et al. . Prospective validation of the lupus impact Tracker: a patient-completed tool for clinical practice to evaluate the impact of systemic lupus erythematosus. Arthritis & Rheumatology 2016;68:1422–31. 10.1002/art.39601
- Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. New York: John Wiley & Sons, Inc, 2004.
- Jenks SA, Cashman KS, Zumaquero E, et al. . Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 2020;52:203. 10.1016/j.immuni.2019.12.005
- Wang D, Huang S, Yuan X, et al. . The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol 2017;14:423-431. 10.1038/cmi.2015.89
- Tran DQ, Andersson J, Wang R, et al. . GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3 + regulatory T cells. Proc Natl Acad Sci U S A 2009;106:13445–50. 10.1073/pnas.0901944106
- Carrillo-Galvez AB, Cobo M, Cuevas-Ocaña S, et al. . Mesenchymal stromal cells express GARP/LRRC32 on their surface: effects on their biology and immunomodulatory capacity. Stem Cells 2015;33:183–95. 10.1002/stem.1821
- Wallace CH, Wu BX, Salem M, et al. . B lymphocytes confer immune tolerance via cell surface GARP-TGF-β complex. JCI Insight 2018;3. 10.1172/jci.insight.99863
- Barbado J, Tabera S, Sánchez A, et al. . Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus 2018;27:2161–5. 10.1177/0961203318804922
- Woodworth TG, Furst DE. Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy. Arthritis Res Ther 2014;16:113. 10.1186/ar4677
- Zhou T, Li H-Y, Liao C, et al. . Clinical efficacy and safety of mesenchymal stem cells for systemic lupus erythematosus. Stem Cells Int 2020;2020:1–11. 10.1155/2020/6518508
- Wen L, Labopin M, Badoglio M, et al. . Prognostic factors for clinical response in systemic lupus erythematosus patients treated by allogeneic mesenchymal stem cells. Stem Cells Int 2019;2019:1–7. 10.1155/2019/7061408
- Galipeau J. The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013;15:2–8. 10.1016/j.jcyt.2012.10.002
- Nie Y, Lau C, Lie A, et al. . Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2010;19:850–9. 10.1177/0961203310361482
- Geng L, Li X, Feng X, et al. . Association of TNF- α with impaired migration capacity of mesenchymal stem cells in patients with systemic lupus erythematosus. J Immunol Res 2014;2014:1–14. 10.1155/2014/169082
- Zhu Y, Feng X. Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus. Stem Cell Res Ther 2018;9:149. 10.1186/s13287-018-0898-x
- Gao J, Dennis JE, Muzic RF, et al. . The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12–20. 10.1159/000047856
- Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009;4:206–16. 10.1016/j.stem.2009.02.001
- Devine SM, Cobbs C, Jennings M, et al. . Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999–3001. 10.1182/blood-2002-06-1830
- Le Blanc K, Frassoni F, Ball L, et al. . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet 2008;371:1579–86. 10.1016/S0140-6736(08)60690-X
- Kean TJ, Lin P, Caplan AI, et al. . Mscs: delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int 2013;2013:1–13. 10.1155/2013/732742
- Wang D, Feng X, Lu L, et al. . A CD8 T Cell/Indoleamine 2,3‐dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatol 2014;66:2234–45. 10.1002/art.38674
- Meisel R, Zibert A, Laryea M, et al. . Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation. Blood 2004;103:4619–21. 10.1182/blood-2003-11-3909
- Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011;6:457–78. 10.1146/annurev-pathol-011110-130230
- Yuan X, Qin X, Wang D, et al. . Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients. Nat Commun 2019;10:2498. 10.1038/s41467-019-10491-8
- de Witte SFH, Luk F, Sierra Parraga JM, et al. . Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells 2018;36:602–15. 10.1002/stem.2779
- Carrión F, Nova E, Luz P, et al. . Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol Lett 2011;135:10–16. 10.1016/j.imlet.2010.09.006
- Jenks PJ, Chevalier C, Ecobichon C, et al. . Identification of nonessential Helicobacter pylori genes using random mutagenesis and loop amplification. Res Microbiol 2001;152:725–34. 10.1016/S0923-2508(01)01253-0
Source: PubMed